Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesEureka AI à l'intérieur
Services professionnels
Témoignages clients
Blog
Rapport mondial sur l'innovation
Glossaire
Newsroom
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport Tovorafenib leads a growing pan-RAF inhibitor pipeline targeting BRAF fusions and mutations in pediatric and adult brain tumors. Explore the patent landscape, combination strategies, and resistance biology.
Article | Rapport Electrochemical CO₂ reduction patent landscape 2026: catalyst design, MEA architecture, cascade reactors, and emerging acidic electrolyte systems analysed across 12 years of filings.
Article | Rapport Explore eVTOL propulsion architectures, hybrid energy systems, and the key certification challenges blocking urban air mobility's commercial deployment.
Article | Rapport Map the 2026 single-cell sequencing patent landscape: key assignees, emerging long-read & multi-omic innovations, geographic trends, and strategic IP white spaces.
Article | Rapport How eVTOL propulsion architectures — electric, hybrid, and tethered — are shaping UAM certification challenges across avionics, safety, and airspace management.
Article | Rapport WEE1 and PKMYT1 inhibitor pipeline in replication stress-high tumors: synthetic lethality strategies, combination regimens, and biomarker stratification insights.
Article | Rapport Analyse the 2026 ultra-low power IoT processor landscape: patent clusters, key assignees, RISC-V trends, zero-power communication, and AI-at-the-edge insights.
Article | Rapport How do swarm robots coordinate warehouse logistics without centralized control? Explore 30+ patents on distributed task allocation, motion planning, and collision avoidance.
Article | Rapport Analyse the 2026 ultra-low power IoT processor landscape: patent clusters, key assignees, RISC-V trends, AI-at-the-edge, and zero-power communication frontiers.
Article | Rapport How synthetic lethality and MTA-cooperative PRMT5 inhibitors are reshaping biomarker-driven oncology for MTAP-deleted cancers. Patent landscape, clinical signals, and emerging strategies.
Article | Rapport How do swarm robots coordinate warehouse logistics without a central controller? Explore 30+ patents on distributed task allocation, collision avoidance, and AI-driven AMR swarms.
Article | Rapport A 2026 patent landscape of exoskeleton technology: AI trajectory planning, modular architectures, rehabilitation, industrial use, and key assignees worldwide.
Article | Rapport Actinium-225 targeted alpha therapy is advancing in prostate and neuroendocrine tumors. Explore the ²²⁵Ac-PSMA-617 pipeline, key assignees, and combination strategies.
Article | Rapport Patent analysis of microplastics detection and removal technologies across spectroscopic, AI-driven, and physical removal systems — mapping the 2026 innovation frontier.
Article | Rapport Iberdomide and mezigdomide are next-generation CELMoDs targeting CRBN to overcome IMiD resistance in RRMM. Explore Phase 3 trial data, combination strategies, and patent landscape.